 CAMBRIDGE, Mass. and GOSSELIES, Belgium, April 10, 2021 GLOBE NEWSWIRE -- iTeos Therapeutics, Inc. Nasdaq: ITOS, clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced a presentation featuring preliminary clinical data from 22 adult patients in the ongoing Phase 12a trial of its anti-TIGIT antibody, EOS-448, at the American Association of Cancer Research AACR Annual Meeting 2021, taking place virtually April 10-15. The presentation highlights initial findings from the completed dose escalation monotherapy portion of the trial, indicating a favorable tolerability profile and early signs of clinical activity in advanced cancers. 